ALK and neuroblastoma: This novel observation due to intra‐tumoral spatial and temporal heterogeneity emphasizes the importance of confirming the continued presence an ALK mutation at relapse prior to the use of ALK inhibitors in relapsed/refractory neuroblastoma.